PerCP/Cyanine5.5 anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1-5_PerCPCyanine55_CD4_Antibody_082418
C57BL/6 mouse splenocytes were stained with CD3e FITC and CD4 (Clone GK1.5) PerCP/Cyanine5.5 (left), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (right).
  • GK1-5_PerCPCyanine55_CD4_Antibody_082418
    C57BL/6 mouse splenocytes were stained with CD3e FITC and CD4 (Clone GK1.5) PerCP/Cyanine5.5 (left), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100433 25 µg 95€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100434 100 µg 259€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  2. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  3. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  4. Wei X, et al. 2022. Cell Rep. 40:111313. PubMed
  5. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  6. Liu N, et al. 2023. Cell Death Dis. 14:170. PubMed
  7. Li G, et al. 2023. Cell Death Dis. 14:185. PubMed
  8. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  9. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  10. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  11. Milighetti M, et al. 2023. iScience. 26:106937. PubMed
  12. Lin CH, et al. 2023. iScience. 26:106904. PubMed
  13. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  14. Hu X, et al. 2022. EBioMedicine. 86:104333. PubMed
  15. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  16. Glaubitz J, et al. 2023. Gut. :. PubMed
  17. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  18. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  19. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  20. Fueyo-González F, et al. 2022. Immunity. 55:459. PubMed
  21. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  22. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  23. Acker A, et al. 2014. PLoS One. 9:110015. PubMed
  24. Miao L, et al. 2020. Theranostics. 0.7625. PubMed
  25. Li X, et al. 2019. Mol Med Rep. 19:4195. PubMed
  26. Romain Bouziat et al. 2018. Cell host & microbe. 24(5):677-688 . PubMed
  27. Tello‐Lafoz M, et al. 2017. Sci Rep. . 10.1038/s41598-017-16370-w. PubMed
  28. Gawish R, et al. 2022. Elife. 11:. PubMed
  29. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  30. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
  31. Wei H, et al. 2021. Malar J. 20:89. PubMed
  32. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  33. Pack AD, et al. 2021. Cell Reports. 36:109586. PubMed
  34. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  35. White MPJ, et al. 2020. Front Immunol. 11:1830. PubMed
  36. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  37. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  38. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  39. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  40. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  41. Hoffmann A, et al. 2021. EBioMedicine. 71:103568. PubMed
  42. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  43. Flaherty S, Reynolds J 2015. J Vis Exp. 98: 52739. PubMed
  44. Wu HL, et al. 2018. J Immunol. 200:49. PubMed
  45. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  46. LaMothe RA et al. 2018. Front Immunol. 0.570138889 . PubMed
  47. Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed
  48. Anderson AM, et al. 2018. J Immunol. 200:2057. PubMed
  49. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  50. Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
  51. Rivadeneira DB, et al. 2020. Immunity. 51(3):548-560. PubMed
  52. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  53. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  54. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  55. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  56. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  57. Wang H, et al. 2021. Malar J. 20:249. PubMed
  58. Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed
  59. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  60. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  61. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  62. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  63. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  64. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  65. Chen Z, et al. 2014. Cancer Immunol Res. 2:911. PubMed
  66. Wang F, et al. 2019. MAbs. 12:1685350. PubMed
  67. Xing Y, et al. 2022. Cancer Lett. 529:100. PubMed
  68. Vogel A, et al. 2022. STAR Protoc. 3:101653. PubMed
  69. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  70. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  71. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  72. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  73. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  74. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  75. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  76. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  77. Song P, et al. 2018. Int J Mol Med. 41:935. PubMed
  78. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  79. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  80. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  81. Pandey S, et al. 2014. J Immunol. 193:3632. PubMed
  82. Di Mitri D, et al. 2019. Cell Rep. 28:2156. PubMed
  83. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  84. Wang Y, et al. 2022. J Control Release. 349:118. PubMed
  85. Abhyankar MM, et al. 2018. NPJ Vaccines. 3:22. PubMed
  86. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  87. Miyauchi E, et al. 2020. Nature. 585:102. PubMed
  88. Li H, et al. 2021. Protein Cell. Online ahead of print. PubMed
  89. Iwata TN, et al. 2018. Mol Cancer Ther. 17:1494. PubMed
  90. He S, et al. 2021. Front Pharmacol. 12:743837. PubMed
  91. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  92. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
  93. Chen HL, et al. 2021. Pharm Biol. 59:134. PubMed
  94. Suhail A, et al. 2019. Cell Rep. 29:3522. PubMed
  95. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  96. Muchenditsi A, et al. 2017. Am J Physiol Gastrointest Liver Physiol. 313:G39. PubMed
  97. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  98. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  99. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  100. Vijay R, et al. 2021. J Exp Med. 218:. PubMed
  101. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  102. Jeon Y, et al. 2015. PLoS One. 10: e0139845. PubMed
  103. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  104. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  105. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  106. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  107. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  108. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  109. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  110. Vijay R, et al. 2020. Nat Immunol. 21:790. PubMed
  111. Li Y, et al. 2020. Front Cell Dev Biol. 8:604021. PubMed
  112. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  113. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  114. Zheng Y, et al. 2022. Transl Res. :. PubMed
  115. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  116. Gawish R, et al. 2022. Elife. 11:. PubMed
  117. Zeng F, et al. 2021. J Invest Dermatol. 596:141. PubMed
  118. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  119. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  120. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  121. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
RRID
AB_893330 (BioLegend Cat. No. 100433)
AB_893324 (BioLegend Cat. No. 100434)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV™ 395 anti-mouse CD4 GK1.5 FC
Go To Top Version: 2    Revision Date: 08/24/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account